April 2017

Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH

​​C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab. Louisville, Ky. – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately. Paul Sekhri is currently CEO and President of the US…